FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis

CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved Vumerity (diroximel fumarate), a novel oral...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news